Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2026-02-09 Regulatory Filings
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, NeuroSense Therapeutics Ltd., submitted to the SEC. It includes an explanatory note about a press release regarding the grant of an Australian patent. The document is short (2232 characters) and primarily furnishes a press release as Exhibit 99.1. There are no financial statements, detailed financial data, or comprehensive reports included. The document serves as a regulatory announcement to inform the market about the press release and is incorporated by reference into other registration statements. According to the rules, such a document is a regulatory filing (RNS) because it does not contain a full report or detailed financial data but is a miscellaneous regulatory announcement.
2026-02-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It details resolutions approved at a Special Meeting of Shareholders, specifically about grants of restricted shares to directors and the CEO. The document is relatively short (2417 characters) and does not contain comprehensive financial statements or detailed financial analysis. It is primarily an announcement of shareholder meeting outcomes and related equity compensation grants. It also references incorporation by reference into registration statements but does not itself constitute a full report like an Annual Report or Interim Report. Given these factors, the document fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-01-06 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a clinical study result and is relatively short (2241 characters). The document states that the press release is attached as Exhibit 99.1 and is furnished herewith, indicating it is an announcement rather than a full report. There are no detailed financial statements or substantive financial data present. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific categories like Annual Report or Interim Report. The document is not a certification or a report publication announcement but a regulatory filing containing a press release.
2025-12-22 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, NeuroSense Therapeutics Ltd., submitted to the SEC. It announces the database lock for a Phase 2 clinical trial and provides information about upcoming topline results and an investor webinar. The document is relatively short (4235 characters) and primarily serves as an announcement of a clinical trial milestone and related investor communication. It does not contain detailed financial statements, comprehensive financial analysis, or full report content. It also includes forward-looking statements and a signature section. Given these characteristics, the document fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-12-08 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about a pre-NDS meeting with Health Canada. The document length is 2125 characters, which is relatively short, and it primarily serves to furnish a press release rather than containing detailed financial statements or substantive financial data. There is no indication of full financial reports, earnings data, or management discussion. The document is an announcement/report filing rather than a full report itself. According to the rules, such filings are best classified under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2025-12-04 English
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a prospectus related to the resale of ordinary shares by a selling shareholder. It includes detailed information about the offering, risk factors, use of proceeds, plan of distribution, and legal matters. The document references a registration statement on Form F-3 filed with the SEC, which is a common form used for securities offerings. The content focuses on the terms and conditions of the share resale, the selling shareholder, and the company's background, rather than financial results or management discussion. This type of document is a capital markets offering document, specifically a prospectus for a share resale offering, which fits the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or any other report type but an update on capital structure and financing activities.
2025-11-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.